GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Douglas B. Snyder sold 4,968 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $14.42, for a total transaction of $71,638.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of NASDAQ GWPH opened at $172.45 on Friday. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $196.00. The stock’s 50 day moving average price is $174.62. The firm has a market capitalization of $5.20 billion, a price-to-earnings ratio of -16.33 and a beta of 2.32. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.19 and a current ratio of 7.81.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.48) by $0.80. The company had revenue of $39.20 million for the quarter, compared to analyst estimates of $12.32 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. GW Pharmaceuticals PLC-‘s revenue for the quarter was up 1189.5% on a year-over-year basis. During the same quarter last year, the business earned ($3.12) EPS. Analysts anticipate that GW Pharmaceuticals PLC- will post -4.76 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in GWPH. Horan Capital Advisors LLC. acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $25,000. Exane Derivatives acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $28,000. TCG Advisors LP acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $29,000. Institutional & Family Asset Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $31,000. Finally, Paragon Capital Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $34,000. Institutional investors own 78.91% of the company’s stock.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.